Digital nuclear morphometry correlates to BAP-1 expression, gene expression

class and metastasis-free survival in uveal melanoma

Christina Herrspiegel[1,2], Thonnie Rose O. See[3], Pia R. Mendoza[4], Hans E.

Grossniklaus[3], and Gustav Stålhammar*[1,2]

[1]St. Erik Eye Hospital, Stockholm, Sweden

[2]Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden, and

[3]Departments of Ophthalmology and Pathology, Emory University School of

Medicine, Atlanta, Georgia, USA.

[4]Department of Pathology and Laboratory Medicine, Emory University School of

Medicine, Atlanta, Georgia, USA.

*Corresponding author

Gustav Stålhammar, M.D. Ph.D. FEBO

Oncology and Pathology service, St. Erik Eye Hospital

Department of Clinical Neuroscience, Karolinska Institutet

Polhemsgatan 50, 112 82

Stockholm, Sweden

Email: gustav.stalhammar@ki.se

Phone: +46 8 672 30 00

ABSTRACT

Cytologic features such as the shape and size of tumor cells can predict metastatic

death in uveal melanoma, but suffer from poor reproducibility. In this study, we

investigate the interobserver concordance of digital morphometry, and correlate the

results with established prognostic markers. The average number of cells analyzed in

each of 27 tumors, was 1957 (SD 349). Mean time consumption was less than 2.5

minutes per tumor. Identical morphometric classification was obtained for $\geq$ 85 % of

tumors in all twelve evaluated morphometric variables (κ 0.70–0.93). The mean

nucleus area, nucleus perimeter, nucleus max caliper and nucleus to cell area ratio

were significantly greater in tumors with low nuclear BRCA associated protein-1

expression (nBAP-1) and gene expression class 2. Patients had significantly shorter

metastasis-free survival if their tumors had low nBAP-1 expression (Log-Rank

p=0.002), gene expression class 2 (Log-Rank p=0.004) or tumor cell nuclei with long

max calipers (Log-Rank p=0.004) as defined in a training cohort and then tested in a

validation cohort. We conclude that digital morphometry can be fast and highly

reproducible, that for the first time, morphometry parameters can be objectively

quantitated in thousands of cells at a time, and that variables describing the shape and

size of the nuclei correlate to nBAP-1 expression, gene expression class and prognosis

in uveal melanoma.

1. Introduction

Uveal melanoma is the most common primary intraocular malignancy in adults (Singh et al., 2014). Less than 5 % of patients have clinically detectable metastases at the time of diagnosis (Singh et al., 2014). At a later stage however, up to 45 % of patients will develop metastases even if the eye containing the tumor has been removed (Kujala et al., 2003). Once macrometastases develop, there is no effective treatment and median patient survival is only 4-12 months (Augsburger et al., 2009; Carvajal et al., 2016).

Several methods for prognostication are in clinical use. Tumor thickness, diameter, location in the eye and presence of distant metastases determine tumor stage (Arnljots et al., 2018; Kivelä et al., 2017). Loss of chromosome 3 has a high positive and negative predictive value for metastasis (Bornfeld et al., 1996). Commercial gene tests based on the expression of 12 classifier genes have been developed and show excellent prognostic utility in separation of class 1 tumors with low metastatic risk from class 2 tumors with high metastatic risk (Onken et al., 2012). Furthermore, we have previously shown the prognostic utility of manual (Szalai et al., 2018) and digital image analysis-based (Stålhammar et al., 2019) determination of the level of nBAP-1.

In 1931, Callender described six types of uveal melanoma based on cytologic features such as cell shape and the size of the nucleus (Callender, 1931). The original classification could accurately predict metastatic death, but suffered from substantial intra- and interobserver discordance (Coleman et al., 1996; Gamel et al., 1992). After several modifications, the morphological classification of uveal melanoma now rely on assessments of the proportion of epitheloid tumor cells (McLean et al., 1983;

Seddon et al., 1987). Examination of cytological features still require a high level of

cytologic expertise and suffer from poor reproducibility (Gamel et al., 1992).

Computer-assisted methods have therefore been proposed as a way of facilitating

these assessments. In 1982, Gamel *et al*. found that 13 of 18 nuclear and nucleolar

features correlated significantly with patient mortality when evaluated with a digitizer

superimposed on microscopic images at a rate of 100 cells per hour (Gamel et al.,

1982). Since then, computers have improved manyfold in terms of their computing

power, cost and the number and scope of software applications and we can now

analyze a dozen of variables or more in thousands of cells per minute on inexpensive

off-the-shelf laptop computers (Stålhammar et al., 2016; Stålhammar et al., 2018).

Consequently, we see an opportunity to analyze cell morphometry features

with digital image analysis and compare these to other prognostic factors including

nBAP-1 expression in uveal melanoma patients from one American and one European

referral center.

2. Methods

2.1. Patients and Samples

The study adhered to the tenets of the Declaration of Helsinki. Methods were carried

out in accordance with the relevant guidelines and regulations. The protocol for

collection of specimens and data from St. Erik Eye Hospital, Stockholm, Sweden was

approved by the regional ethical review board in Stockholm, and the protocol for

collection of specimens and data from Emory Eye Center, Atlanta, GA, USA by the

Emory Institutional Review Board.

Patients were identified in the archives of the Oncology and Pathology

service, St. Erik Eye Hospital and L.F. Montgomery Ophthalmic Pathology

Laboratory, Emory Eye Center. Inclusion criteria were: 1) Enucleation performed

before December 2017, 2) Histologically proven uveal melanoma, 3) paraffin block

available, 4) gene expression classification available, 5) clinicopathological data

available, including tumor thickness, diameter, location, T-category and cell type, 6)

follow-up data available, 7) sufficient tissue for BAP-1 immunohistochemistry.

Exclusion criteria were: 1) Prior history of plaque brachytherapy, proton beam

irradiation and/or transpupillary thermotherapy, and 3) tumor fully necrotic or fully

hemorrhagic. 27 patients met the criteria. Our follow-up data was confirmed and

further extended in telephone interviews with patients or relatives. Informed consent

was obtained from all participants.

In order to establish optimized morphometry thresholds for the distinction of

metastatic versus non-metastatic disease we divided our 27 patients into one training

and one validation cohort. When determining the relative size of the training and

validation cohorts, we considered previous research indicating that the ratio should be

inversely proportional to the square root of the number of free adjustable parameters

(Guyon, 1997). As we only evaluated one morphometric variable at a time, we set the

ratio to 1:1. 13 patients were randomized to the training cohort and 14 to the

validation cohort.

2.2. Immunohistochemistry

The paraffin blocks were cut into 4 μm sections, pretreated in EDTA-buffer at pH 9.0

for 20 minutes and incubated with mouse monoclonal antibodies against BAP-1

(clone C-4, Santa Cruz Biotechnology, Dallas, Texas, USA) and a red chromogen,

and finally counterstained with haematoxylin and rinsed with deionized water. The

deparaffinization, pretreatment, primary staining, secondary staining and

counterstaining steps were run in a Bond III automated IHC/ISH stainer (Leica,

Wetzlar, Germany). Dilutions between 1:20 and 1:500 had been evaluated before

selecting 1:40.

2.3. Digital image analysis

After sectioning and staining, all glass slides were digitally scanned to the .ndpi file

format at ×400, using identical digital scanners at both institutions (Nano Zoomer 2.0

HT, Hamamatsu Photonics K.K., Hamamatsu, Japan). The digital image analysis

(DIA) software used was the QuPath Bioimage analysis v. 0.2.0 m4 (Bankhead et al.,

2017). The software was run on a standard off-the-shelf laptop computer (Apple Inc.

Cupertino, CA).

For assessment of the level of nBAP-1 expression, one positive cell (red

chromogen in nucleus) and one negative cell (haematoxylin but no red chromogen in

nucleus) was calibrated in each digitally scanned tissue section. All other parameters

were left at default in order to limit time consumption and maintain ease of use.

Tumors were then screened under low magnification (40×) and the area exhibiting the

most intense nBAP-1 staining selected for grading. Nuclear immunoreactivity was

evaluated at 200×, in a circular 0.5 mm-diameter region of interest (corresponding to

the field of view in a light microscope with a 400× objective) by automatic

classification (positive cell detection). Based on previous publications, the nBAP-1

expression was classified as "high" if immunoreactivity was detected in >30 % of

tumor cells within the region of interest, and "low" if it was detected in ≤ 30 % of

tumor cells (See et al., 2019; Stålhammar et al., 2019; Szalai et al., 2018).

A workflow for morphometric analysis was then created, including the

following steps for each tumor: A) Identification of all cells within the region of

interest, using the software's cell detection function with the following setttings:

Background nucleus radius 8 μm, median filter radius 0 μm, sigma 1.5 μm, minimum

nucleus area 7.5 μm^2, maximum nucleus area 200 μm^2, threshold 0.1, max

background intensity 2 and cell expansion 5 μm. B) Measurement in each detected

cell in each region of interest of the following 12 cell morphometric variables: 1)

Nucleus area (μm^2). 2) Nucleus perimeter (μm). 3) Nucleus circularity. 4) Nucleus

max caliper (μm). 5) Nucleus min caliper (μm). 6) Nucleus eccentricity. 7) Cell area

(μm^2). 8) Cell perimeter (μm). 9) Cell circularity. 10) Cell max caliper. 11) Cell min

caliper. 12) Nucleus to cell area ratio (figure 1).

Tumor areas with intense inflammation, heavy pigmentation, bleeding,

necrosis or poor fixation were avoided. nBAP-1 classification and morphometric

analysis was performed blinded to all other patient data including outcome. For

measurement of interobserver concordance, two human observers performed the

digital morphometry (morphometric variable above or below median value) and

nBAP-1 classification (high or low) independently and blinded to patient outcomes.

2.4. Gene expression classification

Tumor tissue samples were obtained from freshly enucleated eyes by fine needle

aspiration. The contents of the needle hub were transferred into one of two RNAse-

free cryovials. Using the same needle, extraction buffer from the second cryovial was

aspirated and expelled into the first. This was then placed in a specimen bag,

immediately frozen to -80° C and shipped on dry ice for gene expression classification

based on 12 discriminating genes (*HTR2B, ECM1, RAB31, CDH1, FXR1, LTA4H,*

EIF1B, ID2, ROBO1, LMCD1, SATB1, and *MTUS1*) and 3 control genes (*MRPS21,*

RBM23, and *SAP130*) at a commercial laboratory (Castle Biosciences Inc.

Friendswood, TX, USA). Expression levels of the gene products are used to

categorize tumors as either class 1 with low metastatic risk, or class 2 with high

metastatic risk (Onken et al., 2012).

2.5. Statistical methods

Differences with a $p<0.05$ were considered significant, all p-values being two-sided.

The deviation of all clinicopathological variables from normal distribution was

statistically significant, when evaluated by the Shapiro–Wilk test ($p<0.05$). For

statistical tests of these variables, we therefore used the Mann-Whitney U test, which

does not assume normally distributed data. The deviation of all morphometric

variables from normal distribution was however not statistically significant ($p>0.05$),

why we used Students T-tests for these. For comparisons of categorical variables,

two-by-two tables and Fisher's exact test were used. For correlation to Cox

Proportional Hazards for metastasis and Kaplan-Meier metastasis-free survival,

patients were split into two groups based on 1) the median value of each

morphometric variable, and 2) receiver operating characteristics (ROC) in the training

cohort, with equal emphasis on sensitivity and specificity for the development of

metastasis. The thresholds established in the training cohort were then tested in the

validation cohort. In evaluation of interobserver concordance, the percentage of

identically classified cases and Cohen's kappa statistics (κ) were computed (Cohen,

1960). Metastasis-free follow-up was defined as the time in months from enucleation

to the last occasion patients without metastases was seen or in contact alive. All

statistical analyses were performed using IBM SPSS statistics version 25 (Armonk,

NY, USA).

3. Results

3.1. Descriptive statistics

The mean age at enucleation of patients included in this study was 66 years (SD 15).

Of 27 patients, 15 were men and 12 women. 25 tumors originated in the choroid and 2

in the ciliary body. The cell type was mixed in 18 patients, spindle in 5 and epitheloid

in 4. Mean tumor thickness was 8.6 mm (SD 3.7) and mean diameter 15.8 mm (SD

4.8). 12 tumors were of gene expression class 2 and 15 of class 1a or 1b. 14 tumors

had low nBAP-1 expression and 13 high. Mean metastasis-free follow-up time was 47

months (SD 76, Table 1).

The average number of cells analyzed in each tumor was 1957 (SD 349),

which took an average of 74 seconds (SD 21) for nBAP-1 classification and 71

seconds (SD 17) for morphometric analysis, adding up to 145 seconds or nearly two-

and-a-half minutes per tumor.

3.2. Interobserver concordance

Identical nBAP-1 classification was obtained for 25 of 27 tumors (93 %), yielding a

Cohen's kappa statistic indicating almost perfect agreement (κ=0.85).

206    Identical morphometric classification (morphometric variable above/below

207 median value) was obtained for ≥ 85 % of tumors in all 12 variables, yielding

208 substantial or almost perfect agreement (κ 0.70–0.93, Table 2).

210 *3.3. Morphometry versus nBAP-1 expression and gene expression class*

211 The mean nucleus area, nucleus perimeter, nucleus max caliper and nucleus to cell

212 area ratio were significantly greater in tumors with low nBAP-1 expression. Nucleus

213 circularity, nucleus min caliper, nucleus eccentricity and cell area, cell perimeter, cell

214 circularity, cell max and min caliper were however not significantly different (Table

215 3a).

216    Similarly, the mean nucleus area, nucleus perimeter, nucleus max caliper and

217 nucleus to cell area ratio, but not the other morphometric variables, were significantly

218 greater in tumors of gene expression class 2 (Table 3b).

220 *3.4. Adjusted thresholds*

221 The 4 morphometric variables that correlated to nBAP-1 and gene expression class

222 were analyzed with ROC, with equal emphasis on sensitivity and specificity for the

223 development of metastasis. Mean nucleus area achieved an area under the curve

224 (AUC) of 0.67 (sensitivity 67 %, specificity 50 %, p=0.40) at threshold 27.5 μm^2;

225 Mean nucleus perimeter achieved an area under the curve (AUC) of 0.73 (sensitivity

226 67 %, specificity 70 %, p=0.24) at threshold 21.5 μm; Mean nucleus max caliper

227 achieved an area under the curve (AUC) of 0.80 (sensitivity 67 %, specificity 90 %,

228 p=0.13) at threshold 8 μm; and mean nucleus to cell area ratio achieved an area under

the curve (AUC) of 0.60 (sensitivity 67 %, specificity 50 %, p=0.61) at threshold 0.28

(figure 2).

3.5. Regression analysis and survival

In univariate Cox proportional hazards analyses of nucleus area, nucleus perimeter,

nucleus max caliper and nucleus to cell area ratio, none was an individual predictor of

metastasis (Table 4).

In Kaplan-Meier analysis, patients had significantly shorter metastasis-free

survival if their tumors had low nBAP-1 expression (Log-Rank p=0.002) or gene

expression class 2 (Log-Rank p=0.004), but not if they had a mean nucleus area,

nucleus perimeter, nucleus max caliper and nucleus to cell area ratio greater than the

median (Log-Rank p=0.20–0.83). When using the thresholds established in the

training cohort, mean nucleus max caliper > 8 μm was associated with metastasis-free

survival (Log-Rank p=0.05), whereas the other ROC-adjusted variables did not

separate groups with significant survival differences (Log-rank p=0.18–0.95, figure

3).

4. Discussion

In this study, we have shown that digital image analysis of uveal melanoma cell

morphometry can be fast and highly reproducible, and that variables describing the

shape and size of the nuclei correlate to nBAP-1 expression as well as gene

expression class. Patients with tumors that had large nuclei, as defined by their max

caliper, had significantly worse prognosis. On the other hand, no variable describing

the shape and size of the entire tumor cell correlated to the established prognostic

factors, indicating that for prognosis, the morphological characteristics of tumor

nuclei are more important.

The prognostic importance of cell morphology is by no means a novel

discovery. However, reproducibility, time consumption and level of expertise

required to make reliable assessments of morphometry have limited its utility.

Modern user-friendly digital image analysis techniques offer an attractive solution to

these problems, and for the first time we can now objectively quantitate morphometry

parameters in thousands of cells at a time.

In turn, changes to the size and shape of tumor cells are but a consequence of

changes in the genotype. As found by Onken *et al*. the helix-loop-helix inhibitor *ID2*

suppress the epithelial phenotype associated with an enlarged nucleus (Onken et al.,

2006). Loss of *ID2* up-regulates the epithelial adhesion molecule E-cadherin, which in

turn promotes the anchorage-independent cell growth required for metastasis.

Consequently, we regard the morphometric characteristics investigated here as

biomarkers of the state of the genotype.

Limitations of this study include a small sample size. Inclusion of a larger

number of patients may have revealed additional significant differences. This was

however prevented, primarily by the lack of tumors in our archives for which gene

expression classification was available. Far-reaching conclusions from our survival

analysis are thereby precluded. Substantial investments in digital scanning capacity is

required before the method presented here can be used. The time consumption

specified will most likely be longer for users without general experience in the

operation of home computers, and does not include preanalytical operations such as

digital scanning and loading and unloading of glass slides. Last, our sample is not

representative of all patients with uveal melanoma. We have only investigated the

feasibility of digital morphometry in enucleated specimens without previous plaque

brachytherapy. A large proportion of patients with uveal melanoma undergo primary

plaque brachytherapy or proton beam radiotherapy, and may never require

enucleation. It remains unclear if the digital morphometry characteristics of small

uveal melanomas is different from the relatively large tumors investigated here.

Accordingly, we encourage future studies to confirm these results in larger cohorts

that includes smaller tumors .

Funding

This work was supported in part by Cancerfonden, Karolinska Institutet (Karolinska

Institutets stiftelsemedel för ögonforskning) and Stockholm County Council

(Stockholms läns landsting).

References

Arnljots, T.S., Al-Sharbaty, Z., Lardner, E., All-Eriksson, C., Seregard, S.,
Stålhammar, G., 2018. Tumour thickness, diameter, area or volume? The prognostic
significance of conventional versus digital image analysis-based size estimation
methods in uveal melanoma. Acta Ophthalmol 96, 510-518.
Augsburger, J.J., Corrêa, Z.M., Shaikh, A.H., 2009. Effectiveness of
Treatments for Metastatic Uveal Melanoma. American Journal of Ophthalmology
148, 119-127.
Bankhead, P., Loughrey, M., Fernández, J., Dombrowski, Y., McArt, D.,
Dunne, P., McQuaid, S., Gray, R., Murray, L., Coleman, H., James, J., Salto-Tellez,
M., Hamilton, P., 2017. QuPath: Open source software for digital pathology image
analysis. Sci Rep 7, 16878-16878.
Bornfeld, N., Prescher, G., Becher, R., Hirche, H., Jöckel, K.H., Horsthemke,
B., 1996. Prognostic implications of monosomy 3 in uveal melanoma. The Lancet
347, 1222-1225.

Callender, G., 1931. Malignant Melanotic tumors of the eye. A study of
histologic types in 111 cases. Trans. Am. Acad. Ophthalmol. Otolaryngol. 36, 131-
142.
Carvajal, R.D., Schwartz, G.K., Tezel, T., Marr, B., Francis, J.H., Nathan,
P.D., 2016. Metastatic disease from uveal melanoma: treatment options and future
prospects. British Journal of Ophthalmology.
Cohen, J., 1960. A Coefficient of Agreement for Nominal Scales. Educational
and Psychological Measurement 20, 37-46.
Coleman, K., Baak, J.P.A., van Diest, P.J., Mullaney, J., 1996. Prognostic
Value of Morphometric Features and the Callender Classification in Uveal
Melanomas. Ophthalmology 103, 1634-1641.
Gamel, J.W., McCurdy, J.B., McLean, I.W., 1992. A comparison of
prognostic covariates for uveal melanoma. Investigative ophthalmology & visual
science 33, 1919.
Gamel, J.W., McLean, I.W., Greenberg, R.A., Zimmerman, L.E., Lichtenstein,
S.J., 1982. Computerized histologic assessment of malignant potential: A method for
determining the prognosis of uveal melanomas. Human Pathology 13, 893-897.
Guyon, I., 1997. A scaling law for the validation-set training-set size ratio. At&t Bell
Laboratories, Berkeley California, pp. 1-11.
Kivelä, T., Simpson, E.R., Grossniklaus, H.E., Jager, M.J., Singh, A.D.,
Caminal, J.M., Pavlick, A.C., Kujala, E., Coupland, S.E., Finger, P.T., 2017. Uveal
Melanoma, AJCC Cancer Staging Manual, 8 ed. Springer, Chicago, pp. 805-817.
Kujala, E., Mäkitie, T., Kivelä, T., 2003. Very long-term prognosis of patients with
malignant uveal melanoma. Invest Ophthalmol Vis Sci 44, 4651-4659.
McLean, I., Foster, W., Zimmerman, L., Gamel, J., 1983. Modifications of
Callender's classification of uveal melanoma at the Armed Forces Institute of
Pathology. Am J Ophthalmol 96, 502-509.
Onken, M.D., Ehlers, J.P., Worley, L.A., Makita, J., Yokota, Y., Harbour,
J.W., 2006. Functional gene expression analysis uncovers phenotypic switch in
aggressive uveal melanomas. Cancer research 66, 4602.
Onken, M.D., Worley, L.A., Char, D.H., Augsburger, J.J., Correa, Z.M.,
Nudleman, E., Aaberg, T.M., Altaweel, M.M., Bardenstein, D.S., Finger, P.T., Gallie,
B.L., Harocopos, G.J., Hovland, P.G., McGowan, H.D., Milman, T., Mruthyunjaya,
P., Simpson, E.R., Smith, M.E., Wilson, D.J., Wirostko, W.J., Harbour, J.W., 2012.
Collaborative Ocular Oncology Group report number 1: prospective validation of a
multi-gene prognostic assay in uveal melanoma. Ophthalmology 119, 1596-1603.
Seddon, J.M., Polivogianis, L., Hsieh, C.-C., Albert, D.M., Gamel, J.W.,
Gragoudas, E.S., 1987. Death From Uveal Melanoma: Number of Epithelioid Cells
and Inverse SD of Nucleolar Area as Prognostic Factors. Archives of Ophthalmology
105, 801-806.
See, T.R.O., Stålhammar, G., Phillips, S.S., Grossniklaus, H.E., 2019. BAP1
Immunoreactivity Correlates with Gene Expression Class in Uveal Melanoma. Ocular
Oncology and Pathology, 1-9.
Shields, C.L., Furuta, M., Thangappan, A., Nagori, S., Mashayekhi, A., Lally,
D.R., Kelly, C.C., Rudich, D.S., Nagori, A.V., Wakade, O.A., Mehta, S., Forte, L.,
Long, A., Dellacava, E.F., Kaplan, B., Shields, J.A., 2009. Metastasis of Uveal
Melanoma Millimeter-by-Millimeter in 8033 Consecutive Eyes. Archives of
Ophthalmology 127, 989-998.

Singh, N., Bergman, L., Seregard, S., Singh, A.D., 2014. Epidemiologic Aspects, in:
Damato, B., Singh, A.D. (Eds.), Clinical Ophthalmic oncology: Uveal tumors, 2 ed.
Springer, Berlin, Heidelberg, pp. 75-87.
Stålhammar, G., Fuentes Martinez, N., Lippert, M., Tobin, N.P., Mølholm, I.,
Kis, L., Rosin, G., Rantalainen, M., Pedersen, L., Bergh, J., Grunkin, M., Hartman, J.,
2016. Digital image analysis outperforms manual biomarker assessment in breast
cancer. Modern pathology : an official journal of the United States and Canadian
Academy of Pathology, Inc 29, 318.
Stålhammar, G., Robertson, S., Wedlund, L., Lippert, M., Rantalainen, M.,
Bergh, J., Hartman, J., 2018. Digital image analysis of Ki67 in hot spots is superior to
both manual Ki67 and mitotic counts in breast cancer. Histopathology 72, 974-989.
Stålhammar, G., See, T.R.O., Phillips, S., Seregard, S., Grossniklaus, H.E.,
2019. Digital Image Analysis of BAP-1 Accurately Predicts Uveal Melanoma
Metastasis. Translational vision science & technology 8, 11.
Szalai, E., Wells, J.R., Ward, L., Grossniklaus, H.E., 2018. Uveal Melanoma
Nuclear BRCA1-Associated Protein-1 Immunoreactivity Is an Indicator of Metastasis.
Ophthalmology 125, 203-209.

Legends

Figure 1. Illustration of cell morphometric measurements. A) Calipers denotes the

largest and smallest diameters of the nucleus and cell. Nucleus eccentricity is a

measure of how much the nucleus deviates from a spherical shape, presented as a

number between 0.00 and 1.00. A completely spherical nucleus have an eccentricity

of 0.00, a nucleus with the shape of an elliptical 3D solid would have an eccentricity

of 0.5, whereas a 3D conical distribution would have a value of 1.00. Circularity

compares the perimeter of a shape to the area it contains, and is calculated by four

times π times the area divided by the perimeter squared. The circularity of a circle is

1.00, and less for less circular objects. B) A circular 0.5 mm-diameter region of

interest (corresponding to the field of view in a light microscope with a 400×

objective) was defined in each tumor. Within this region of interest, each cell was

analyzed for nBAP-1 expression and 12 morphometric variables describing the size

and shape of cells and nuclei. C) The morphometric variables have been automatically

identified within the region of interest shown in B. D and E) In another tumor, cells

have slightly larger, more rounded nuclei with prominent nucleoli, corresponding to

what would be known as epitheloid cells. Cell illustration by iStock.com/Vitalii

Dumma, East Ukraine Volodymyr Dahl National University Scale bars: 100 μm..

n =	27
Mean age at diagnosis, years (SD)	66 (15)
Sex, n (%)	
Female	15 (56)
Male	12 (44)
Primary tumor location, n (%)	
Choroid	25 (93)
Ciliary body	2 (7)
Iris	0 (0)
Cell type, n (%)	
Spindle	5 (19)
Epitheloid	4 (15)
Mixed	18 (67)
Mean tumor thickness, mm (SD)	8.6 (3.7)

Mean tumor diameter, mm (SD)	15.8 (4.8)
Previous brachytherapy or TTT, n (%)	
No	27 (100)
Yes	0 (0)
AJCC T-category, n (%)	
1	0 (0)
2	7 (26)
3	14 (52)
4	6 (22)
Gene expression class, n (%)	
1a	9 (33)
1b	6 (22)
2	12 (44)
DIA nBAP-1 classification, n (%)	
High	13 (48)
Low	14 (52)
Follow-up months, mean (SD)[§]	47 (76)

393   Table 1. Characteristics of patients and tumors included in this study. SD, standard

394   deviation. TTT, Transpupillary thermotherapy.

	Interobserver concordance (%)	Cohen's κ
Nucleus area	85	0.70
Nucleus perimeter	85	0.70
Nucleus circularity	96	0.93
Nucleus caliper, max	85	0.70
Nucleus caliper, min	89	0.78
Nucleus eccentricity	96	0.93
Cell area	85	0.70
Cell perimeter	85	0.70
Cell circularity	93	0.85
Cell caliper, max	85	0.70

Cell caliper, min	85	0.70
Nucleus to cell area ratio	96	0.93

396   Table 2. Interobserver concordance and Cohen's kappa statistics in classification of

397   each morphometric variable as above or below the median value.

	nBAP-1 high (n=13)	nBAP-1 low (n=14)	*P*
Nucleus area, μm^2 (SD)	24.31 (4.38)	28.34 (3.40)	0.013
Nucleus perimeter, μm (SD)	19.61 (1.78)	21.37 (1.28)	0.0066
Nucleus circularity	0.76 (0.04)	0.75 (0.04)	0.41
Nucleus caliper, max μm (SD)	7.52 (0.65)	8.21 (0.58)	0.0074
Nucleus caliper, min μm (SD)	4.43 (0.59)	4.67 (0.36)	0.20
Nucleus eccentricity (SD)	0.76 (0.03)	0.77 (0.04)	0.52
Cell area, μm^2 (SD)	88.50 (15.10)	94.58 (12.42)	0.26
Cell perimeter, μm (SD)	37.05 (3.26)	38.33 (2.53)	0.26
Cell circularity	0.77 (0.01)	0.77 (0.01)	0.70
Cell caliper, μm (SD)	13.62 (1.22)	14.09 (0.97)	0.27
Cell caliper, μm (SD)	9.00 (0.79)	9.29 (0.59)	0.30
Nucleus to cell area ratio	0.28 (0.03)	0.30 (0.02)	0.031

399   Table 3a.

400   Average values and Students T-tests of cell morphometric variables in tumors of high

401   versus low nBAP-1 expression. SD, standard deviation.

	Gene expression class 1a or 1b (n=15)	Gene expression class 2 (n=12)	*P*
Nucleus area, μm^2 (SD)	24.89 (4.40)	28.28 (3.59)	0.041
Nucleus perimeter, μm (SD)	19.84 (1.76)	21.37 (1.39)	0.0022
Nucleus circularity	0.76 (0.04)	0.75 (0.04)	0.42

Nucleus caliper, max μm (SD)	7.59 (0.63)	8.23 (0.63)	0.016
Nucleus caliper, min μm (SD)	4.48 (0.57)	4.65 (0.37)	0.39
Nucleus eccentricity (SD)	0.76 (0.03)	0.77 (0.04)	0.33
Cell area, μm^2 (SD)	89.90 (14.59)	93.83 (13.16)	0.48
Cell perimeter, μm (SD)	37.34 (3.13)	38.18 (2.70)	0.47
Cell circularity	0.77 (0.01)	0.77 (0.01)	0.64
Cell caliper, max μm (SD)	13.71 (1.15)	14.06 (1.05)	0.42
Cell caliper, min μm (SD)	9.23 (0.61)	9.23 (0.61)	0.62
Nucleus to cell area ratio	0.28 (0.03)	0.30 (0.02)	0.024

Table 3b.

Average values and Students T-tests of cell morphometric variables in tumors of gene

expression class 1a or 1b versus 2. SD, standard deviation.

Figure 2.

Receiver operating characteristics (ROC) of the mean nucleus area, nucleus

perimeter, nucleus max caliper and nucleus to cell area ratio in the training cohort

(*n*=13), with equal emphasis on sensitivity and specificity for the development of

metastasis. Mean nucleus area (blue line) achieved an area under the curve (AUC) of

0.67 (sensitivity 67 %, specificity 50 %, p=0.40) at threshold 27.5 μm^2; Mean nucleus

perimeter (pink line) achieved an area under the curve (AUC) of 0.73 (sensitivity 67

%, specificity 70 %, p=0.24) at threshold 21.5 μm; Mean nucleus max caliper (green

line) achieved an area under the curve (AUC) of 0.80 (sensitivity 67 %, specificity 90

%, p=0.13) at threshold 8 μm; and mean nucleus to cell area ratio (orange line)

achieved an area under the curve (AUC) of 0.60 (sensitivity 67 %, specificity 50 %,

p=0.61) at threshold 0.28.

	Regression coefficient, β (SE)	Wald statistic	*P*	Hazard coefficient, Exp(b) (95 % CI)
Univariate Cox proportional hazards				
Nucleus area ≥ median	0.2 (0.7)	0.05	0.83	1.17 (0.3–4.8)
Nucleus perimeter ≥ median	0.9 (0.7)	1.5	0.22	2.5 (0.6–10.4)
Nucleus caliper, max ≥ median	0.9 (0.7)	1.5	0.22	2.5 (0.6–10.4)
Nucleus to cell area ratio ≥ median	0.4 (0.7)	0.4	0.52	1.6 (0.4–5.9)

Table 4.

Cox Proportional Hazards analysis of the association between metastasis-free survival

and cell morphometric variables. No method was individually associated with

shortened metastasis-free survival.

SE, standard error.

Figure 3.

Kaplan-Meier curves, cumulative metastasis-free survival. A) Patients with tumors

with high nBAP-1 expression (yellow) versus low (blue), as defined by digital image

analysis using a mean of <30 % stained tumor nuclei as cutoff (Log-Rank p=0.002).

B) Patients with tumors of gene expression class 1a or 1b (yellow) versus 2 (blue,

Log-Rank p=0.004). C) Patients in the validation cohort (*n*=14) with mean nucleus

max caliper ≤ 8 μm (yellow) versus > 8 μm (blue), which was the threshold

established in the training cohort (Log-Rank p=0.05).